Blog

In a new study, Tokyo Medical and Dental University researchers shed light on partial endothelial-to-mesenchymal transition in the tumor microenvironment Credit: Dr. Kazuki Takahashi from Tokyo Medical and Dental University, Japan In a new study, Tokyo Medical and Dental University researchers shed light on partial

PLYMOUTH MEETING, PA [February 7, 2024] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today published its first ever set of treatment recommendations pertaining to neuroblastoma. Neuroblastoma is a type of solid tumor cancer that typically occurs in early childhood, with the

Accelerating Innovation in Medicine – Health Initiative (AIM-HI) is proud to celebrate a significant milestone in the journey of one of its esteemed portfolio companies, Yiviva. A clinical-stage platform biotechnology company, Yiviva has entered into a Memorandum of Understanding (MOU) with AstraZeneca China, a multinational

Hepatocellular carcinoma (HCC) is a common disease in human history and one of the main causes of cancer-related death. Sorafenib (SORA) is the best representative of angiogenesis inhibitors and is currently being commonly used in the treatment of advanced HCC as a first-line drug. Although SORA improves the

Women have a four times higher risk of dying from cardiovascular disease if they have an infection with a high-risk strain of the human papillomavirus (HPV), according to research published in the European Heart Journal [1] today (Wednesday). Credit: European Heart Journal Women have a

New findings led by researchers at the American Cancer Society (ACS) and the National Cancer Institute (NCI) show more than one-third of cancer patients had a major adverse financial event – bankruptcy, lien, or eviction – before their cancer diagnosis. These patients with adverse financial

An international team of researchers identifies the genetic basis and biological processes that influence cancer risk related to alterations in the number of immune cells present in blood. This is a significant advance in the understanding of how the immune system can prevent the appearance

  Credit: VHIO   Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has widely been considered as an undruggable cancer target. Published today in

In a new paper published in Cancer Research, a journal of the American Association for Cancer Research, researchers at MUSC Hollings Cancer Center have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can restore the effectiveness of the breast cancer

FEBRUARY 2, 2024, NEW YORK – Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized